1. Introduction {#Section1}
===============

Interleukin-18 (IL-18) gene was first isolated and cloned from propioibacteriumacnes-treated and lipopolysaccharide-treated mouse livers in 1995 by 0kamura [@B1]. IL-18 was discovered as an interferon (IFN-γ)-inducing factor and had a critical role in inflammatory and immune response [@B2]. It stimulates natural killer (NK) and T cells and enhances Th1 immune response. IL-18 is a proinflammatory cytokine with biological properties similar to IL-12 [@B3]. As a member of the IL-1 family, other functions ascribed to IL-18 include induction of IL-1β, tumor necrosis factor-α (TNF-α), production of granulocyte/macrophage colony stimulation factor (GM-CSF) and IL-2 by T cells [@B4], as well as enhancement of NK cell cytotoxicity and neutrophil activity, enhancement of Fas ligand expression by Th1 cells, and anti-tumor effects were reported [@B5]. The expression and secretion of IL-18 is shown in various kinds of cells from immune cells such as macrophages, T cells and neutrophils to cancer cells [@B6], it induces IFN-γ production from T cells without the requirement for T-cell receptor (TCR) engagement [@B7]. So, the crucial function of IL-18 as an immunomodulatory molecule is used for antitumor.

Recently, some cancer cells such as prostate cancer cells and esophageal cancers have been reported to secrete IL-18 [@B8],[@B9], so the role of IL-18 needs to be investigated in cancers. Some reports showed that IL-18 increases in the serum of the majority of cancer patients and has been associated with disease progression [@B10], suppression of IL-18 bioactivity as a novel therapeutic concept for the treatment of chronic inflammatory [@B11]. However, a large number of tests showed that IL-18 eliminates spontaneous cancer or pathogen infected cells [@B12],[@B13], and IL-18 was applied to an adjuvant of vaccines.

IL-18 is a multifunctional cytokine that induces IFN-γ secretion and play an important role in antitumor immunity [@B14]. Pro-IL-18, does not contain a known signal peptide-sequence, and is converted into functional active mature protein by proteolytic cleavage of IL-1β converting enzyme (ICE) resulting in an 18.3 kDa final molecule [@B12], variations in the DNA sequences of IL-18 may lead to altered IL-18 production and/or activity, we constructed IL-18 mutants by cutting the hIL-18 cDNA, to investigate the secretion characteristics of IFN-γ, IL-2, IL-18, and protein distribution, antigenicity with hIL-18 mutants in pancreatic cancer BxPC-3 cells line.

2. Materials and methods {#Section2}
========================

2.1 Plasmids and cell culture {#Section2.1}
-----------------------------

Eukaryotic expression vector pEGFP-C1 was purchased from Clontech (Palo Alto, USA). pGEM-T-hIL-18 was conserved in our laboratory.*E. coli* DH-5α were purchased from TAKARA (Dalian,China). BxPC-3 cells were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM; Gibco,Gaithersburg, USA) supplemented with 10% fetal bovine serum (FBS; Gibco), 100 IU/ml penicillin and 100 μg/ml streptomycin at 37 ºC with 5% CO2.

2.2 Construction of recombinant eukaryotic expression plasmids {#Section2.2}
--------------------------------------------------------------

According to the sequence of hIL-18 cDNA gene provided by GenBank, four various hIL-18 sequences were amplified with primer pairs (Table [1](#T1){ref-type="table"}) from pGEM-T-hIL-18 (presaved in our lab), respectively. The cutting ATG ORF of hIL-18 were amplified with primer pairs P1/P2 forming sequence Mu0 (sMu0). Assuming that the hIL-18 protein is cleaved at the 36th amino acid residue after the conserved aspartate residue, we amplify a cDNA fragment encoding an N-terminal truncated form (sMu1) of hIL-18 with primer pairs P3/P4. To investigate the influences with an incomplete sequence of hIL-18, N-terminal 56 amino acid peptide truncated form (sMu2) and C-terminal 20 amino acid peptide truncated form (sMu3) were amplified by PCR, middle mino acid peptide (P^124^-P^143^) truncated form (sMu4) of hIL-18 was synthesized by TaKaRa Biotechnology (Dalian) Company. Each fragments of hIL-18 were inserted into pEGFP-C1 after digestion with restriction enzymes, resulting in recombinant plasmids Mu0 (containing the complete ORF of *hIL-18*), Mu1, Mu2, Mu3 and Mu4 (Figure [1](#F1){ref-type="fig"}, table [1](#T1){ref-type="table"} showed primers).

All recombinant plasmid were identified with restriction enzymes, and sequencing by TaKaRa Biotechnology (Dalian) Company. The fused proteins of green fluorescent protein (GFP) and IL-18 can be observed by confocal laser scanning microscope.

2.3 Transfection of five recombinant plasmids and pEGFP-C1 into BxPC-3 cells {#Section2.3}
----------------------------------------------------------------------------

The pancreatic cancer cell line BxPC-3 was obtained from the Shanghai Institute for Biological Sciences, Chinese Academy of Science (SIBS/CAS), and cultured in RPMI1640 (HyClone, Logan, USA) supplemented with 10% FBS, 100 IU/ml penicillin and 100 μg/ml streptomycin at 37ºC with 5% CO2. After 48 h, BxPC-3 cells were centrifugated at 1000 *g* for 5 min, and 6-well plated at 1×10^5^cells/well in growth medium without antibiotics. Five recombinant plasmids and pEGFP-C1(0.8ug/well) were transferred into adherent BxPC-3 cells using Lipofectamine™ 2000 (Invitrogen, Carlsbad,USA) as its instructions [@B15]. The transfection rate assayed was about between 29% and 31% by fluorescent microscopy.

2.4 Proliferation response of BxPC-3 cells transfected with recombinant plasmids by MTT assay {#Section2.4}
---------------------------------------------------------------------------------------------

BxPC-3 cells were cultured for four days in RPMI1640 medium containing 10% FBS. Cell suspension was inoculated to each well of 96-well plates (each well has a total volume of 100 μL, density of 1×10^4^cells/well. After 24 h, five recombinant plasmids and pEGFP-C1 were transfected into BxPC-3 cells, of which the treatment concentration were 0.4ug/well, 0.2ug/well and 0.1ug/well. Each well repeated three times. At different post-transfection time points (12 h, 24 h, 36 h, 48 h ), cells were observed under a contrast phase microscope before adding MTT solution, prepared fresh as 5 mg/ml in ddH~2~O and filtered through a 0.22 μm filter, and kept for 10 min at 60ºC. 10 µl of MTT solution was added to each well incubated in the dark at 37ºC for 4 h. Then MTT/medium was removed and 150 µl DMSO was added to each well. The OD values were measured at 570 nm using Model 680 Microplate reader as figure [2](#F2){ref-type="fig"} (Bio-RAD).

2.4 Analysis of hIL-18 expression by RT-PCR and enzyme-linked immunosorbent assay (ELISA) {#Section2.4_1}
-----------------------------------------------------------------------------------------

Five recombinant plasmids and pEGFP-C1 were transfected into BxPC-3 cells. At different post-transfection time points, the cells transfected were digested with 0.25% trypsin and 0.02% EDTA and collected into 1.5 ml Eppendorf tubes. The transcriptions of target genes were determined by reverse transcription (RT)-PCR with primers β-actin and hIL-18 full length respectively using the total RNA extracted from cells 12 h, 24 h, 36 h, 48 h post-transfection as the template (Figure [3](#F3){ref-type="fig"}). At the same time,the cultivation supernatant was transferred from each of all the wells to each of 1.5 ml Eppendorf tubes and measured by ELISA. Briefly, Enzyme-linked immunosorbent assay (ELISA) were carried out to determine protein expression using hIL-8 ELISA Kit, IFN-γ ELISA Kit and IL-2 ELISA Kit (Cusabio, Wuhan, China) according to the manufacturer\'s protocol. Each well repeated three times.

2.5 Intracellular Distribution of five Fused GFP-IL-18 in BxPC-3 cells {#Section2.5}
----------------------------------------------------------------------

The cell culture was similar as above, 100 μL of cell suspension was inoculated to each well of 96-well plates and transfected with five recombinant plasmids (Mu0, Mu1, Mu2, Mu3, Mu4) and pEGFP-C1 (as control), At different post-transfection time points (12 h, 24 h, 36 h, 48 h), cells were examined under laser confocal microscopy 510 (Zeiss, Oberkochen, Germany) for Green fluorescent distribution.

2.6 Statistical Analysis {#Section2.6}
------------------------

All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS ®) version 18.0 (SPSS, Inc. Chicago, IL, USA). The differences in the measurement data were compared using the Student\'s *t* test, and comparisons between groups were tested using the χ2 test or the Fisher exact probability test. *P* \< 0.05 was considered statistically significant.

3. Results {#Section3}
==========

3.1 MTT assays of BxPC-3 cells transfected with five IL-18 recombinant plasmid {#Section3.1}
------------------------------------------------------------------------------

IL-18 has been shown to have significant antitumor activity in several preclinical animal models. Phase I clinical trials of recombinant human IL-18 have demonstrated that it can be safely administered to patients with advanced cancer (16). MTT assay is a conventional experiment for cells proliferation. MTT results showed that the BxPC-3 cells with five recombinant plasmids all had the most effective inhibition at 24 h post-transfection, and Mu1 had the best effective inhibition. Differences between Mu1, Mu2 and the pEGFP-C1 control group were significant (*P*\<0.05). But Mu0, Mu3, Mu4 compared to the pEGFP-C1 control group had no significant difference (*P*\>0.05) (Figure [2](#F2){ref-type="fig"}).

3.2 RT-PCR products of five recombinant plasmids {#Section3.2}
------------------------------------------------

RT-PCR results of BxPC-3 cells transfected with five recombinant plasmid and pEGFP-C1, respectively. Fig.[3](#F3){ref-type="fig"}A showed the cDNA of five recombinant plasmids (Mu0, Mu1, Mu2, Mu3, Mu4), pEGFP-C1 and untreated BxPC-3 cells were amplified with primers of β-actin, which was confirmed that RNA extraction and reverse transcription into cDNA was successful. Fig.[3](#F3){ref-type="fig"}B and [3](#F3){ref-type="fig"}D showed the hIL-18 cDNA were amplified from five recombinant plasmids (Mu0, Mu1, Mu2, Mu3, Mu4), pEGFP-C1 and untreated BxPC-3 cells using the primer of hIL-18 full length, but the bands were light expect Mu0, Which indicated that pro-IL-18 was low expression in BxPC-3 cells transfected. The cDNA of five recombinant plasmids (Mu0, Mu1, Mu2, Mu3, Mu4) were amplified successfully using the original primers from Fig.[3](#F3){ref-type="fig"}C, which demonstrated that five recombinant plasmids were transfected into BxPC-3 cells successfully and expressed.

3.3 Analysis of hIL-18 expression in BxPC-3 cells by ELISA {#Section3.3}
----------------------------------------------------------

Differences in the DNA sequences of IL-18 may lead to altered IL-18 production, the antigenity of hIL-18 maybe change after it mino acid peptide cutting. The results showed that the expression of hIL-18 in BxPC-3 cells with five recombinant plasmids rapid rise at peak value after12 h transfected, and appeared small-crest at 36h post-transfection, but the expression of hIL-18 was decreased gradually between 36h and 48h post-transfection. Comparing with the control group (pEGFP-C1), Mu0, Mu1, Mu2, Mu3, and Mu4 had the significant difference (*P*\<0.05) (Figure [4](#F4){ref-type="fig"} and table [2](#T2){ref-type="table"}).

3.4 Analysis of IFN-γ induction in BxPC-3 cells by ELISA {#Section3.4}
--------------------------------------------------------

Predominantly biologic effects of IL-18 include activation of monocytes, NK cells, and production of IFN-γ as well as other cytokines in vivo (16), the expression of IFN-γ in BxPC-3 cells were increased with five recombinant plasmids after 12h transfected, but the expression of IFN-γ was decreased slowly soon. The expression of IFN-γ was more steady on observation points, only small-fluctuation after high expression. Comparing with the control group (untreated BxPC-3 cells), Mu0, Mu1, Mu2, Mu3, and Mu4 had the significant difference (*P*\<0.01) (Table [3](#T3){ref-type="table"}). The difference between the pEGFP-C1 group and control group was not significant (*P*\>0.05) (Figure [5](#F5){ref-type="fig"} and Table [3](#T3){ref-type="table"}).

3.5 Analysis of IL-2 induction in BxPC-3 cells by ELISA {#Section3.5}
-------------------------------------------------------

The result of hIL-2 ELISA data analysis showed that Mu0, Mu1, Mu2, Mu3, and Mu4 had no difference comparing with the control group (untreated BxPC-3 cells), which pointed that pancreatic cancer BxPC-3 cells line may not express hIL-2 (*P\>0.05*) (Results not showed).

3.6 Expression and localization of recombinant hIL-18-EGFP {#Section3.6}
----------------------------------------------------------

To further investigate the intracellular distribution of recombinant hIL-18-EGFP hIL-18 Mu0, Mu1, Mu2, Mu3, Mu4 and pEGFP-C1 were transfected into BxPC-3 cells. The fused proteins were expressed and observed by laser confocal microscopy 510 (Figure [6](#F6){ref-type="fig"}). The fluorescence intensity of transfected with pEGFP-C1 was continuously bright after transfected 12h to 48h. The transfected cells presented a diffusing and uniform fluorescence throughout the cytoplasm and nucleus 12 h post-transfection, fluorescence intensity of other cells are decreasing after transfected with Mu 0, Mu 1, Mu 2, Mu 3, Mu 4 12h to 48h, and the fluorescence of the hIL-18 Mu1 and Mu 2 appeared targeted to the membranous region of the BxPC-3 cells.

4. Discussion {#Section4}
=============

Bioactive IL-18 induces IFN-γ production, Fas Ligand (FasL) expression, and inhibits angiogenesis, raising the issue of anti-tumor effects of a tumor-derived cytokine in pancreatic carcinoma cells [@B17]. In this work, we cut the N-terminal 36 amino acid peptide (form of Mu1, presumed mature protein gene), N-terminal 56 amino acid peptide (form of Mu2), C-terminal 20 amino acid peptide (form of Mu3), and middle 20 amino acid peptide (form of Mu4) of hIL-18 cDNA respectively, which were inserted into pEGFP-C1. The recombinant plasmids were transfected into BxPC-3 cells for proliferation inhibition, MTT results showed that both Mu1 and Mu2 groups showed significant (*P*\<0.05) compared with pEGFP-C1 transfected control cells. It was proved that mature form of IL-18 with functional activity in antitumor [@B18], so the growth inhibition of Mu1 in BxPC-3cells is understandable, but the growth inhibition of Mu2 suggested that the inhibition activity is related with cut forepart and integrate middle and later amino acid peptide of IL-18. Interestingly, as Fig. [6](#F6){ref-type="fig"} showed, the fluorescence of the Mu1 and Mu 2 appeared targeted to the membranous region of the BxPC-3 cells after transfected 24h to 48h, these results suggest that the N-terminal forepart amino acid peptide of hIL-18 presumed mature protein probably exposed by cutting, and combine to some membrane proteins of BxPC-3 cells, the same situation was reported in chicken IL-18 [@B19]. Maybe there are relationship between inhibition activity and the intracellular distributions of IL-18, which perhaps indicated that truncated former amino acid peptide of hIL-18 lead to intracellular distributions variations of IL-18, and bring about growth inhibition differences in BxPC-3 cells.

The results of RT-PCR products and expression level of hIL-18 in BxPC-3 cells revealed that five recombinant plasmids were transfected into BxPC-3 cells successfully, and all mutants of IL-18 were active in IL-18 induction (*P*\<0.05), although quantity of induced IL-18 were decreased rapidly, autocrine expression of IL-18 in BxPC-3 cells is transient. The antigenicity of IL-18 were not changed by our cutting of N-terminal, middle and C-terminal amino acid peptide, it display that antigenic determinant of IL-18 perhaps is multiple locus or multiple repeated.

IL-18 is constitutively produced by dendritic cells and several cells line [@B17], autocrine IL-18 induced high level IFN-γ. The secretion of IFN-γ in BxPC-3 cells by IL-18 mutants was significant increased (*P*\<0.01), and there was no statistical difference in the expression level of transfected pEGFP-C1 and untreated BxPC-3 cells (*P*\>0.05). The secretion of IFN-γ was not changed with hIL-18 mutants, maybe the determinant of IFN-γ secretion was not cleaved by our truncated. IL-18 level in BxPC-3 cells with IL-18 mutants seems dose not corresponding to MTT results, the reason is not clear. The expression of IL-2 with recombinant plasmids was no statistical difference comparing with BxPC-3 cells (*P*\>0.05), it pointed that IL-2 neither secreted by BxPC-3 cells, no induced by increasing of IL-18 and IFN-γ in BxPC-3 cells.

IL-18 is proposed as novel adjuvant cancer therapy, but the role of the proinflammatory IL-18 in cancer progression remains controversial; our results showed that variations in the DNA sequences of IL-18 may change IL-18 distribution in vitro, but not changed activity for IFN-γ and IL-18 secretion in BxPC-3 cells. A lot of reports suggest that careful preclinical studies are needed to determine the proper application of IL-18 in cancer therapy, there are a lot of works for various domain function of IL-18, make an intensive study for better comprehension and application in future.
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![Recombinant plasmids construction of Mu0, Mu1, Mu2, Mu3, Mu4.](ijmsv11p0172g001){#F1}

![**Effects of transfection of five recombinant plasmids on BxPC-3 cells\' proliferation.** The treatment concentration of A to C were 0.4ug/well, 0.2ug/well and 0.1ug/well. The statistics showed that the five recombinant plasmids all had the most effective inhibition at 24 h post-transfection, among which Mu1 had the best effective inhibition.](ijmsv11p0172g002){#F2}

![**RT-PCR products of five recombinant plasmids.**M: 100-6000 bp DNA Marker.**(A)**Lane 1-20 showed the RT-PCR results of BxPC-3 cells tranfected with five recombinant plasmids (Mu0, Mu1, Mu2, Mu3,Mu4) at 12 h, 24 h, 36 h, 48 h respectively, using the primer of β-actin. **(B)**Lane 1-20 showed the RT-PCR results of BxPC-3 cells tranfected with five recombinant plasmids (Mu0, Mu1, Mu2, Mu3, Mu4) at 12 h, 24 h, 36 h, 48 h respectively, using the primer of hIL-18 full length. Lane 21 is negative control. **(C)**Lane1-20 showed the RT-PCR results of BxPC-3 cells tranfected with five recombinant plasmids (Mu0, Mu1, Mu2, Mu3, Mu4) at 12 h, 24 h, 36 h, 48 h respectively, using the original primers. **(D)**Control. Lane 1-4 and lane 5-8 showed RT-PCR results of BxPC-3 cells tranfected with pEGFP-C1 and untreated BxPC-3 cells cultivated at 12 h, 24 h, 36 h, 48 h respectively, using the primer of hIL-18 full length. Lane 9-12 and lane 13-16 showed RT-PCR results of BxPC-3 cells with the same treatment (according to Lane 1-4 and 5-8) using the primer of β-actin.](ijmsv11p0172g003){#F3}

![**Analysis of hIL-18 expression in BxPC-3 cells (by hIL-18 ELISA kit). (A)** The standard curve of hIL-18 ELISA kit. **(B)** The different expression levels of hIL-18 in the cultivation supernatant of BxPC-3 cells after post-transfection of five recombinant plasmids at 0, 12, 24, 36, 48 h.](ijmsv11p0172g004){#F4}

![**Analysis of IFN-γ expression in BxPC-3 cells (by IFN-γ ELISA kit). (A)** The standard curve of IFN-**γ**ELISA kit. (B) The different expression levels of IFN-**γ**in the cultivation supernatant of BxPC-3 cells after post-transfection of five recombinant plasmids at 0 h, 12 h, 24 h, 36 h, 48 h.](ijmsv11p0172g005){#F5}

![**Localization of enhanced green fluorescent protein (EGFP)-tagged hIL-18 recombinant plasmids inBxPC-3 cells.** Confocal micrographs of transfected BxPC-3 cells expressing EGFP-tagged hIL-18 recombinant plasmid at 12 h post-transfection **(A)**24 h post-transfection, **(B)**36 h post-transfection, **(C)**48 h post-transfection, **(D)**and composite photo**(E)**respectively**.**Images were taken in the plane where maximum fluorescence appeared. Transfected cells presented uniform fluorescence throughout the cytoplasm and the nucleus 12 h post-transfection, and the fluorescence intensity of transfected cells with pEGFP-C1 are durable(A-D), fluorescence intensity of other cells are decreasing. But from 24 h and 36 h post-transfection, the fluorescence of the hIL-18 Mu1 and Mu2 appeared targeted to the membranous region of the BxPC-3 cells. Magnification, 200×.](ijmsv11p0172g006){#F6}

###### 

Sequence of primers used in the experiments

  Primer   Nucleotide sequence                   Location   Restriction enzyme
  -------- ------------------------------------- ---------- --------------------
  P1       TCA *CTCGAG* CTGCTGCTGAACCAGTAGAAG    4-24       *Xh*oⅠ
  P2       CGA *GAATTC*CTAGTCTTCGTTTTGAACAGTG    583-604    *Eco*RⅠ
  P3       CT *GGTACC* TACTTTGGCAAGCTTGAATCTAA   112-134    *Kp*nⅠ
  P4       CA*GGATCC* CTAGTCTTCGTTTTGAACAGTGA    583-605    *Bam*HⅠ
  P5       G*GAATTC* ATTCATTGACCAAGGAAATCGGC     172-194    *Eco*RⅠ
  P6       TC *GGTACC* CTAGTCTTCGTTTTGAACAGTG    583-604    *Kp*nⅠ
  P7       GG *GGTACC* CTGCTGCTGAACCAGTAGAAG     4-24       *Kp*nⅠ
  P8       G*GGATCC* TAAATGAGTTTAAAAAGGTCTC      523-544    *Bam*HⅠ

Restriction enzyme sites are in italic.

###### 

hIL18 ELISA data analysis

  Sample    OD (Mean ±SD)   *P* value                                               
  --------- --------------- ------------- ------------- ------------- ------------- --------
  Mu0       1.524±0.091     1.973±0.104   1.593±0.075   1.400±0.124   1.147±0.060   \<0.01
  Mu1       1.458±0.111     2.060±0.105   1.470±0.165   1.431±0.110   1.179±0.061   \<0.05
  Mu2       1.472±0.089     1.928±0.139   1.532±0.135   1.440±0.064   1.066±0.017   \<0.05
  Mu3       1.447±0.127     2.048±0.130   1.589±0.168   1.315±0.156   1.227±0.055   \<0.05
  Mu4       1.431±0.111     1.936±0.093   1.575±0.191   1.292±0.127   1.083±0.032   \<0.05
  Control   1.004±0.124     1.245±0.113   1.379±0.150   1.124±0.073   1.071±0.147   

OD: Optical density as 492 wavelength

###### 

IFN-γ ELISA data analysis

  Sample    OD (Mean ±SD)   P value                                                 
  --------- --------------- ------------- ------------- ------------- ------------- ----------
  Mu0       2.633±0.114     2.528±0.046   2.684±0.174   2.673±0.021   2.585±0.217   *\<0.01*
  Mu1       2.633±0.049     2.543±0.041   2.631±0.085   2.659±0.044   2.642±0.026   *\<0.01*
  Mu2       2.676±0.088     2.505±0.173   2.620±0.022   2.655±0.114   2.626±0.042   *\<0.01*
  Mu3       2.688±0.068     2.490±0.053   2.623±0.020   2.692±0.073   2.550±0.126   *\<0.01*
  Mu4       2.655±0.039     2.445±0.022   2.640±0.006   2.605±0.111   2.628±0.018   *\<0.01*
  C1        1.887±0.072     1.965±0.064   1.965±0.057   2.114±0.079   2.405±0.081   *\>0.05*
  Control   1.930±0.171     2.168±0.165   2.111±0.100   2.485±0.173   2.489±0.241   

OD: Optical density as 492 wavelength
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